Show simple item record

dc.contributor.authorDesert, Romain
dc.contributor.authorNieto, Natalia
dc.contributor.authorMusso, Orlando
dc.date.accessioned2019-01-09T17:25:15Z
dc.date.available2019-01-09T17:25:15Z
dc.date.issued2018-10
dc.identifier.issn1007-9327
dc.identifier.other10.3748/wjg.v24.i40.4536
dc.identifier.urihttp://hdl.handle.net/10027/23194
dc.description.abstractHepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death worldwide. More than 80% of HCCs arise within chronic liver disease resulting from viral hepatitis, alcohol, hemochromatosis, obesity and metabolic syndrome or genotoxins. Projections based on Western lifestyle and its metabolic consequences anticipate a further increase in incidence, despite recent breakthroughs in the management of viral hepatitis. HCCs display high heterogeneity of molecular phenotypes, which challenges clinical management. However, emerging molecular classifications of HCCs have not yet formed a unified corpus translatable to the clinical practice. Thus, patient management is currently based upon tumor number, size, vascular invasion, performance status and functional liver reserve. Nonetheless, an impressive body of molecular evidence emerged within the last 20 years and is becoming increasingly available to medical practitioners and researchers in the form of repositories. Therefore, the aim this work is to review molecular data underlying HCC classifications and to organize this corpus into the major dimensions explaining HCC phenotypic diversity. Major efforts have been recently made worldwide toward a unifying “clinically-friendly” molecular landscape. As a result, a consensus emerges on three major dimensions explaining the HCC heterogeneity. In the first dimension, tumor cell proliferation and differentiation enabled allocation of HCCs to two major classes presenting profoundly different clinical aggressiveness. In the second dimension, HCC micro­environment and tumor immunity underlie recent the­rapeutic breakthroughs prolonging patients’ survival. In the third dimension, metabolic reprogramming, with the recent emergence of subclass-specific metabolic profiles, may lead to adaptive and combined therapeutic approaches. Therefore, here we review recent molecular evidence, their impact on tumor histopathological features and clinical behavior and highlight the remaining challenges to translate our cognitive corpus into patient diagnosis and allocation to therapeutic options.en_US
dc.description.sponsorshipThe authors thank the following members of the Institut NuMeCan, at INSERM in Rennes, France: Anne Corlu, for helpful discussion and inspiring remarks; Bruno Clément, for critical reading of the manuscript and helpful suggestions; Michèle Le Guennec, Patricia Jouas and Thomas Poussou for efficient secretarial assistance. We thank Christelle Reynès and Robert Sabatier, Biostatistics and Informatics laboratory, Pharmacy School, University of Montpellier, France and Pierre-Antoine Eliat, Small Animal Imaging Core Facility, Rennes 1 University, INSERM, CNRS, for enlightening discussions.en_US
dc.language.isoenen_US
dc.publisherBaishideng Publishing Groupen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectLiver metabolismen_US
dc.subjectLiver zonationen_US
dc.subjectHepatocellular carcinoma classificationen_US
dc.subjectInflammationen_US
dc.titleDimensions of hepatocellular carcinoma phenotypic diversityen_US
dc.typeArticleen_US
dc.identifier.citationDesert, R., Nieto, N., & Musso, O. (2018). Dimensions of hepatocellular carcinoma phenotypic diversity. World Journal of Gastroenterology, 24(40), 4536-4547. doi:10.3748/wjg.v24.i40.4536en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States